Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.

Scientific reports - 31 Oct 2023

Witz Andréa, Dardare Julie, Francois Aurélie, Husson Marie, Rouyer Marie, Demange Jessica, Merlin Jean-Louis, Gilson Pauline, Harlé Alexandre

Abstract excerpt

Pancreatic cancer is one of the most aggressive diseases with a very poor outcome. Olaparib, a PARP inhibitor, as maintenance therapy showed benefits in patients with metastatic pancreatic adenocarcinoma bearing germline BRCA1/2 mutations. However, germline BRCA mutation has been described in only 4-7% of patients with pancreatic adenocarcinoma. A CRISPR/Cas9-mediated system was used to knock-in the c.763G > T...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to CRISPR-Cas Systems

Share to Germ-Line Mutation

Share to MCF-7 Cells

Share to Pancreatic Neoplasms

Share to Phthalazines

Source

Open in PubMed Open full text

Identifiers

PMID: 37907567
DOI: 10.1038/s41598-023-45964-w
PMCID: PMC10618219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.PMID 37907567Read ↗

CRISPR/Cas9-Mediated Knockdown Of BRCA1/2 Restores Response To Olaparib In Pancreatic Cancer Cell LinesSemantic proximity Read ↗

CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlookSemantic proximity Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines.Semantic proximity Read ↗

CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancersSemantic proximity Read ↗

An evaluation of olaparib for the treatment of pancreatic cancer.Semantic proximity Read ↗

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read ↗

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read ↗

The role of PARP inhibitors in BRCA mutated pancreatic cancerSemantic proximity Read ↗

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsSemantic proximity Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.